CNS biotech firms invite Biovail to the table
This article was originally published in Scrip
Executive Summary
Biovail Pharmaceuticals will continue to buy its way into the central nervous disease market having identified several potential neurological acquisitions. The Canadian firm will pursue external targets with future growth after losing out to Lundbeck's $900 million buyout of Ovation Pharmaceuticals.